Zacks Investment Research upgraded Nantkwest Inc (NASDAQ:NK) to Hold in a statement released today.
- Updated: October 2, 2016
Zacks Investment Research has upgraded Nantkwest Inc (NASDAQ:NK) to Hold in a statement released on 09/28/2016.
Yesterday Nantkwest Inc (NASDAQ:NK) traded 5.14% higher at $7.85. Nantkwest Inc’s 50-day average is $8.03 and its two hundred day average is $7.65. The last close is up 1.63% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 201,599 shares of the stock traded hands, down from an average trading volume of 253,778
With a market capitalization of $0, Nantkwest Inc has 52 week low of $5.43 and a 52 week high of $19.43 .
A total of 6 brokers have issued a research note on the company. 0 analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero brokerages rating the company a hold, zero firms rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $26.17.
Brief Synopsis About Nantkwest Inc (NASDAQ:NK)
NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, non-hodgkin lymphoma and myelodysplastic syndrome.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.